A side-by-side comparison of two Healthcare investors: Deerfield Management (Power Score 83/100) and Vivo Capital (Power Score 83/100), both ranked among the most active firms tracked in this category.
| Deerfield Management | Vivo Capital | |
|---|---|---|
| Power Score™ | 83/100 | 83/100 |
| Assets Managed | More than $16B (in assets as of December 2025, per the firm's own About page; the figure could not be checked against Form ADV Item 5.F) | $6.1B ("Active AUM" as of Q4 2025, the label the firm uses on its own homepage; it separately stated approximately $5.3B of regulatory assets under management in its 7 May 2025 fund-close announcement) |
| Founded | 1994 | 1996 |
| Headquarters | New York, NY | Palo Alto, CA |
| Sectors | Therapeutics, Medical Devices, Healthcare, Diagnostics, Digital Health, Life Sciences | Healthcare, Biotech, Pharmaceuticals, Life Sciences, Healthtech |
Deerfield describes itself as an investment firm dedicated to advancing healthcare through investment, intelligence and philanthropy, and says it holds a portfolio of more than two hundred private and public investments spanning therapeutics, medical devices, healthcare services, diagnostics and digital health. It states that it invests across capital structures and across company stages, from early-stage startups to mature companies, and that it offers structured finance solutions and customised financing for entrepreneurs and corporate partners in both public and private markets. Alongside the funds it runs an in-house research and data organisation: Deerfield Intelligence is described as the firm's data, technology and AI arm, and Deerfield Discovery and Development (3DC) as its internal R&D engine, taking early-stage therapeutics from discovery through preclinical proof of concept into clinical development. Deerfield also builds companies with academic and health-system partners through named discovery alliances. It is an SEC-registered investment adviser (CRD 157876, SEC file 801-73284) and files quarterly 13F reports covering listed equities, ADSs and convertible notes, so its public-market activity sits alongside its private investing rather than replacing it.
View full Deerfield Management profile →Vivo Capital describes itself as a global healthcare specialist running a multi-strategy investment platform that covers venture capital, private equity and public equity. Its investment strategy page names three distinct strategies: the Vivo Innovation Fund, which invests in venture-stage companies developing healthcare technologies or products; Vivo Capital Private Equity, which combines growth capital for companies at commercial inflection points with a buyout strategy covering leveraged buyouts, management buyouts, spin-offs and restructurings; and the Vivo Opportunity Fund, a long-only strategy investing primarily in global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies through follow-ons, PIPEs, registered directs and IPOs. The firm states it has invested in over 460 healthcare companies and operates from Palo Alto with offices in China and a presence in Singapore.
View full Vivo Capital profile →